Literature DB >> 16444382

Trimethoprim-sulfamethoxazole versus norfloxacin in the prophylaxis of spontaneous bacterial peritonitis in cirrhosis.

Roberto Fiolic Alvarez1, Angelo Alves de Mattos, Esther Buzaglo Dantas Corrêa, Helma Pinchemel Cotrim, Tereza Virginia S B Nascimento.   

Abstract

BACKGROUND: The prognosis of patients with chronic liver disease and spontaneous bacterial peritonitis is poor, being of great importance its prevention. AIM: To compare the effectiveness of trimethoprim-sulfamethoxazole versus norfloxacin for prevention of spontaneous bacterial peritonitis in patients with cirrhosis and ascites. PATIENTS AND METHODS: Fifty seven patients with cirrhosis and ascites were evaluated between March 1999 and March 2001. All of them had a previous episode of spontaneous bacterial peritonitis or had ascitic fluid protein concentration < or = 1 g/dL and/or serum bilirubin > or = 2.5 mg/dL. The patients were randomly assigned to receive either 800/160 mg/day of trimethoprim-sulfamethoxazole 5 days a week or 400 mg of norfloxacin daily. The mean time of observation was 163 days for the norfloxacin group and 182 days for the trimethoprim-sulfamethoxazole group. In the statistical analysis, differences were considered significant at the level of 0.05.
RESULTS: According to the inclusion criteria, 32 patients (56%) were treated with norfloxacin and 25 (44%) with trimethoprim-sulfamethoxazole. Spontaneous bacterial peritonitis occurred in three patients receiving norfloxacin (9.4%) and in four patients receiving trimethoprim-sulfamethoxazole (16.0%). Extraperitoneal infections occurred in 10 patients receiving norfloxacin (31.3%) and in 6 patients receiving trimethoprim-sulfamethoxazole (24.0%). Death occurred in seven patients (21.9%) who received norfloxacin and in five (20.0%) who received trimethoprim-sulfamethoxazole. Side effects occurred only in the trimethoprim-sulfamethoxazole group.
CONCLUSION: In spite of the reduced number of patients and time of observation, trimethoprim-sulfamethoxazole and norfloxacin were equally effective in spontaneous bacterial peritonitis prophylaxis, suggesting that trimethoprim-sulfamethoxazole is a valid alternative to norfloxacin.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16444382     DOI: 10.1590/s0004-28032005000400012

Source DB:  PubMed          Journal:  Arq Gastroenterol        ISSN: 0004-2803


  7 in total

1.  Targeting the Homoserine Dehydrogenase of Paracoccidioides Species for Treatment of Systemic Fungal Infections.

Authors:  Mariane C Bagatin; Arethusa L Pimentel; Débora C Biavatti; Ernani A Basso; Erika S Kioshima; Flavio A V Seixas; Gisele de F Gauze
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

2.  Diagnosis and management of bacterial infections in decompensated cirrhosis.

Authors:  Maria Pleguezuelo; Jose Manuel Benitez; Juan Jurado; Jose Luis Montero; Manuel De la Mata
Journal:  World J Hepatol       Date:  2013-01-27

3.  Systemic review and network meta-analysis: Prophylactic antibiotic therapy for spontaneous bacterial peritonitis.

Authors:  Nolan Faust; Akihiro Yamada; Haider Haider; Yuga Komaki; Fukiko Komaki; Dejan Micic; Atsushi Sakuraba
Journal:  World J Hepatol       Date:  2020-05-27

4.  Risk factors of cellulitis in cirrhosis and antibiotic prophylaxis in preventing recurrence.

Authors:  Rooby Erachamveettil Hamza; Mashhood Padincharepurathu Villyoth; George Peter; Deni Joseph; Chethan Govindaraju; Devang Chandrakanth Tank; Sreejaya Sreesh; Premalatha Narayanan; Kattoor Ramakrishnan Vinayakumar
Journal:  Ann Gastroenterol       Date:  2014

5.  ASEPTIC: primary antibiotic prophylaxis using co-trimoxazole to prevent SpontanEous bacterial PeritoniTIs in Cirrhosis-study protocol for an interventional randomised controlled trial.

Authors:  Dominic Crocombe; Norin Ahmed; Indran Balakrishnan; Ekaterina Bordea; Marisa Chau; Louise China; Lynsey Corless; Victoria Danquah; Hakim-Moulay Dehbi; John F Dillon; Ewan H Forrest; Nick Freemantle; David Peter Gear; Coral Hollywood; Rachael Hunter; Tasheeka Jeyapalan; Yiannis Kallis; Stuart McPherson; Iulia Munteanu; Jim Portal; Paul Richardson; Stephen D Ryder; Amandeep Virk; Gavin Wright; Alastair O'Brien
Journal:  Trials       Date:  2022-09-27       Impact factor: 2.728

6.  Antibiotic prophylaxis to prevent spontaneous bacterial peritonitis in people with liver cirrhosis: a network meta-analysis.

Authors:  Oluyemi Komolafe; Danielle Roberts; Suzanne C Freeman; Peter Wilson; Alex J Sutton; Nicola J Cooper; Chavdar S Pavlov; Elisabeth Jane Milne; Neil Hawkins; Maxine Cowlin; Douglas Thorburn; Brian R Davidson; Emmanuel Tsochatzis; Kurinchi Selvan Gurusamy
Journal:  Cochrane Database Syst Rev       Date:  2020-01-16

Review 7.  Antibiotics and Liver Cirrhosis: What the Physicians Need to Know.

Authors:  Caterina Zoratti; Rita Moretti; Lisa Rebuzzi; Irma Valeria Albergati; Antonietta Di Somma; Giuliana Decorti; Stefano Di Bella; Lory Saveria Crocè; Mauro Giuffrè
Journal:  Antibiotics (Basel)       Date:  2021-12-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.